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Abstract
Mutations in isocitrate dehydrogenase (IDH) are the most prevalent genetic abnormalities in lower 
grade gliomas. The presence of these mutations in glioma is prognostic for better clinical 
outcomes with longer patient survival. In the present study, we found that defects in oxidative 
metabolism and 2-HG production confer chemosensitization in IDH1-mutated glioma cells. In 
addition, temozolomide (TMZ) treatment induced greater DNA damage and apoptotic changes in 
mutant glioma cells. The PARP1-associated DNA repair pathway was extensively compromised in 
mutant cells due to decreased NAD+ availability. Targeting the PARP DNA repair pathway 
extensively sensitized IDH1-mutated glioma cells to TMZ. Our findings demonstrate a novel 
molecular mechanism that defines chemosensitivity in IDH-mutated gliomas. Targeting PARP-
associated DNA repair may represent a novel therapeutic strategy for gliomas.
Introduction
Mutations in isocitrate dehydrogenase (IDH1/2) are common genetic abnormalities in grade 
II and III diffusive astrocytomas and oligodendrogliomas(1). In WHO grade II/III gliomas, 
IDH mutated tumors are highly prevalent comprising nearly 80% of all clinical cases(2). In 
glioma, IDH mutations cluster in an arginine residue at the center of the catalytic domain 
(IDH1 R132, IDH2 R172). Mutant IDH confers neomorphic enzymatic activity that, 
catalyzes α-ketoglutarate (α-KG) into 2-hydroxyglutarate (2-HG), an oncometabolite 
closely related to the deactivation of α-KG-dependent deoxygenases(3,4). For example, 
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IDH1 mutant derived 2-HG promotes hypoxia signaling by perturbing the catalytic activity 
of prolyl hydroxylase, resulting in constitutive activation of hypoxia-inducible factor 1α 
(HIF-1α)(5). Additionally, 2-HG has also been found to affect collagen maturation and 
basement membrane function, which may facilitate cancer cell infiltration and promote 
glioma progression(6). Clinically, the occurrence of IDH mutations predicts longer survival 
and greater sensitivity to chemotherapy in low-grade gliomas and secondary 
glioblastomas(7,8). A phase III clinical trial has provided the direct link between IDH 
mutation and survival benefit from chemotherapy(9). Combined with O-6-methylguanine-
DNA methyltransferase (MGMT) promoter methylation status, IDH mutations serve as an 
important prognostic marker for gliomas treated with radiation and chemotherapy(10). 
Although there has been increasing awareness of the correlation between IDH mutations and 
chemo-sensitivity, the molecular mechanism that determines the vulnerability that results 
from IDH mutations remains unanswered.
DNA repair is defined as a series of molecular changes that occur in response to 
compromised chromosomal integrity. DNA repair is integral to cancer therapies based on 
generating DNA damage in chromosomal DNA, such as radiation therapy and cytotoxic 
chemotherapies(11). The activation and expression level of DNA repair pathways largely 
determines the efficacy of chemotherapies and resulting clinical outcomes(12,13). Several 
studies shed light on the changes in DNA repair mechanism in IDH1-mutated cells, 
including RAD51 and ATM pathways(14,15). The distinct connection between DNA repair 
pathway and chemo-sensitivity in IDH-mutated cells, however, must be further elucidated.
In the present study, we established cell lines that stably expresses either the IDH1R132C or 
IDH1R132H pathogenic mutations. We demonstrate that our cell lines recapitulate the IDH1-
mutant phenotypes found in glioma patients. The IDH1 mutations resulted in the metabolic 
reprogramming and cytotoxic effects via 2-HG production. In addition, cells with mutant 
IDH failed to form the poly (ADP-ribose) polymer (pADPR), and therefore were unable to 
maintain genomic integrity. Furthermore, targeting the PARP DNA repair mechanism 
remarkably potentiated the cytotoxic effects of chemotherapy. Taken together, our findings 
indicate a potential molecular mechanism of chemo-sensitization in IDH mutant gliomas 
and, suggests a novel therapeutic strategy for clinical therapies.
Materials and Methods
Cell Culture and Reagents
The U251 MG cell line was obtained from Sigma Aldrich in 2015. The U87 MG, HT1080 
and LN-18 glioma cell lines were acquired from the American Type Culture Collection 
(ATCC) in 2015. Each cell line was tested and authenticated by their manufacturers. Cells 
were cultured in Dulbecco Modified Eagle Medium-Ham F-12 medium (DMEM/F-12, 1:1, 
Life Technologies) supplemented with the 10% fetal bovine serum (Cellgro) and 1% 
antibiotics (100 U/ml penicillin and 10 µg/ml streptomycin) at 37 °C in a humidified air with 
5% CO2. Temozolomide (TMZ, Sigma) or DMSO (Fisher Scientific) was added to cell 
cultures. Dimethyl ester of 2-hydroxyglutaric acid was synthesized and kindly provided by 
Dr. Stephen Frye’s lab at UNC School of Pharmacy.
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Lentivirus or retrovirus production and stable cell line generation
U87 and U251 stable cell lines ectopically expressing wild type IDH1, R132C or R132H 
variants, as well as HT1080 cells with stable IDH1 gene knockdown were created. For IDH1 
knockdown, pLKO.1 plasmids carrying either a non-target or IDH1-specific short hairpin 
RNA (shRNA) sequences were purchased from Sigma (St. Louis, MO). The IDH1-specific 
shRNA sequence was: 5’- CCG GGC TGC TTG CAT TAA AGG TTT ACT CGA GTA 
AAC CTT TAA TGC AAG CAG CTT TTT-3’. The lentivirus was packaged using HEK 
293T cells. Virus containing supernatant was added to cells and the infection was carried out 
for another 48 hr. Medium was changed to fresh culture medium supplemented with 
puromycin (1-2 µg/ml). IDH1 gene expression and knockdown was confirmed by Western 
blot analysis.
Cell Viability Analysis
The MTS cell proliferation (Promega) and CCK-8 assays (Dojindo) were used to determine 
the number of viable cells according to the manufacturer’s protocol. Cell viability was 
measured by optical absorbance on an Epoch plate reader (BioTek).
Flow Cytometry
Cells were collected and fixed in ice-cold 75% ethanol overnight, and centrifuged at 3,000 g 
for 10 min. Cell pellets were mixed with 200 µl ethanol and RNA was removed by RNase 
treatment. Cellular DNA content was investigated by propidium iodide (PI) staining. Stained 
cells were analyzed on FACSCanto II (BD).
Apoptosis Assay
Cell apoptosis was analyzed by Annexin V/7-AAD or Annexin V/PI kit (Thermo Fisher) 
according to the manufacturer’s protocol. Cells were collected and analyzed on FACS Canto 
II (BD) flow cytometer.
DNA fragmentation assay
Genomic DNA was isolated from cells using DNeasy Blood & Tissue Kit (QIAGEN). Fifty 
nanograms of DNA was resolved by electrophoresis on a 10% Novex TBE gel. The gel was 
probed with SYBR Safe DNA Gel stain and visualized on the Bio-Rad ChemiDoc Imaging 
System.
Immunoblotting
Total protein was isolated from cultured cells using RIPA lysis buffer supplemented with 
protease and phosphatase inhibitor cocktail (Thermo Fisher). Cell lysates were sonicated and 
centrifuged at 12,000 g for 25 minutes. Protein content was determined using the BCA 
protein assay (Thermo Scientific). Protein extracts (25 μg/lane, for all tested proteins) were 
separated on NuPAGE 4 - 12% Bis-Tris minigels (Life Technologies) and transferred to 
Immobilon-P polyvinylidene fluoride (PVDF) membranes (Millipore). Blots were probed 
with primary antibodies and visualized by chemiluminescence according to the 
manufacturer’s protocol (Thermo Fisher). The primary antibodies used include: All histone 
specific antibodies were used according to manufacturer’s recommendation (CST), 
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endostatin (Abcam), IDH1 (CST), IDH1 R132H (Dianova), PARP1 (CST), pADPR 
(Abcam), β-actin (Sigma), and FLAG M2-HRP (Sigma).
Comet assay
The Comet assay was performed as previously described(16). Cells were resuspended in 
0.75% agarose and placed on glass slides. Cells were lysed in 1.2 M NaCl, 100 mM EDTA, 
0.1% sodium lauryl sarcosinate, and 0.26 M NaOH (pH > 13). Electrophoresis of the cells 
was performed at a voltage of 0.6 V/cm for 30 min. DNA were labelled with SYBR Safe 
DNA Gel stain and visualized under a Zeiss LSM710 confocal microscope.
Seahorse metabolic assay
Seahorse XF Cell Mito Stress assays were performed according to the manufacturer’s 
protocol. Twenty thousand cells were seeded in a poly-D-lysine coated 96-well plate. Cells 
were treated with oligomycin (1 µM), FCCP (2 µM), and antimycin/rotenone (0.5 µM) 
sequentially. The oxygen consumption rate was recorded and calculated for baseline 
respiration and maximal respiration.
Determining 2-hydroxyglutarate concentration.
Intracellular 2-HG concentration was determined by either nuclear magnetic resonance 
(NMR) or colorimetric assay (BioVision). For NMR analysis, culture media were removed 
and cells were scraped in ice-cold acetonitrile (Sigma) and mixed with 2/3 volume of cold 
water. The total extract was evaporated in a Speed-Vac. Prior to analysis, the dried cell 
extract pellet was suspended in water containing 0.1 mM 3-trimethylsilyl-propionic acid 
(TSP), vortexed, and filtered into 5 mm NMR tubes. Chenomx NMR Suite (version 6.01; 
Chenomx Inc.) was used for spectral processing, metabolite identification and quantification.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism software (Version 6.05, 
GraphPad Software, Inc.). Data were displayed as mean ± SEM. Statistical comparisons 
were conducted using One-way ANOVA or independent Student’s t-test.
Results
IDH1-mutated glioma cells are sensitive to TMZ
Emerging clinical observations indicate remarkably different clinical outcomes in glioma 
patients depending on the IDH mutation status of their cancer. IDH mutations appear to be 
associated with a better response to chemotherapies such as TMZ(9,10 ,17). To better 
understand the molecular basis of IDH-associated chemo-sensitivity, we established IDH1 
mutant cells by stably expressing IDH1 mutants (IDH1R132C or IDH1R132H) in U87 MG or 
U251 MG cell lines. We found that IDH1 mutant cells were more vulnerable to TMZ 
treatment in vitro. Assessing cell viability under different doses of TMZ revealed that the 
dose-response curves were significantly shifted leftwards in mutant cells (p<0.01, Figure 
1A). The IC50 of TMZ was reduced in IDH1R132C and IDH1R132H cells (for U251 cells, 
IC50 IDH1WT=1791 µM; IC50 IDH1R132C=715.9 µM; IC50 IDH1R132H= 772.6 µM), 
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suggesting that a smaller dose of TMZ are sufficient to achieve cytotoxic effects in IDH 
mutant cells. TMZ-induced apoptosis was enhanced in IDH mutant cells, as Annexin-V 
labeled cells were more abundant in IDH1R132H cells (Figure 1B, Annexin-V+ cells 
IDH1WT=22.5%; Annexin-V+ cells IDH1R132H=34.2%). The enhanced chemo-sensitivity 
was further verified through propidium iodide (PI) staining followed by cell cycle analyses 
(Figure 1C). We demonstrated impaired cell cycle progression with G2/M arrest in both 
IDH1WT and IDH1R132H cells treated with TMZ, which is consistent with the finding that 
TMZ induces G2/M arrest in glioma cells(18). Notably, the population of cells in G2/M 
arrest was markedly increased in IDH1 mutant cells (for U251 cells, G2/M IDH1WT=26.6%; 
G2/M IDH1R132H=56.8%), suggesting a greater incidence of failed cell cycle progression in 
mutant cells during treatment. As a further validation of cellular apoptosis, we also 
investigated the dynamic change of TMZ-induced DNA fragmentation (Figure 1D). TMZ 
treatment resulted in the accumulation of small molecular weight of fragmented DNA over a 
4-day time course. The amount of fragmented DNA was increased by 2.21-fold in 
IDH1R132H cells, indicating an increased tendency for apoptosis in IDH mutant cells in the 
presence of TMZ.
Enhanced DNA damage in IDH1 mutant glioma cells
The increase in G2/M arrest is a common phenomenon when cells fail to proceed to the 
DNA damage checkpoint, suggesting that the chemo-sensitivity of IDH1 mutant cells is 
linked to their vulnerability to DNA damage. To test this hypothesis, we evaluated TMZ-
induced DNA damage in IDH1 mutant cells by measuring γH2A.X (Figure 2A). TMZ 
exposure resulted in a remarkable increase in γH2A.X expression in all cell lines. TMZ 
induced more robust expression of γH2A.X in IDH1R132C cells compared to wild type (0.89 
AU and 1.84 AU for IDH1WT and IDH1R132C, respectively, by densitometry analysis). 
Interestingly, the baseline H2A.X phosphorylation in mutant cells was also elevated, 
indicating severe intrinsic dysfunction in DNA repair machinery (0.21 AU and 0.57 AU for 
IDH1WT and IDH1R132C, respectively). We confirmed DNA damage through in situ labeling 
of γH2A.X puncta in the nucleus (Figure 2B). Consistent with previous findings, the 
baseline DNA damage was also elevated in mutant cells (0.0036 AU, 0.018 AU and 0.032 
AU for IDH1WT, IDH1R132C and IDH1R132H, respectively). To better understand the 
integrity of genomic DNA in IDH1 mutant cells, we analyzed the proportion of fragmented 
DNA through comet assay (Figure 2C). We confirmed the baseline DNA damage by 
increased fragmented DNA in IDH1R132C and IDH1R132H cells without any treatment, as 
shown by elongated comet tail under electric field. TMZ treatment resulted in significant 
DNA fragmentation, and the fragmented DNA is more abundant in IDH1R132C and 
IDH1R132H cells. Quantitative analysis confirmed more DNA damage occurred in IDH1 
mutant cells (Figure 2D).
Metabolic reprogramming results in chemo-sensitivity in IDH1-mutated cells
Mutations in IDH1 establishes neomorphic catalytic activity, which redirects carbon 
metabolites away from the Kreb cycle towards 2-HG production(19,20). Metabolic defects 
and reprogramming could be one of the causes of chemo-sensitivity. To test this, we studied 
the oxidative metabolism in IDH1 mutant cells through the Seahorse metabolic assay 
(Figure 3A). The decrease in oxygen consumption rate (OCR) in IDH1-mutated cells 
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suggested significantly reduced oxidative metabolism. Quantitative analyses confirmed a 
significant decrease in both baseline and maximum capacity of oxidative metabolism in 
mutant cells (Figure 3B and C). Moreover, we found a significant increase in intracellular 2-
HG in mutant cells (Figure 3D). The 2-HG production could be reversed by treatment with 
AGI-5198, a specific chemical inhibitor targeting the R132H variant of IDH1 enzyme(21). 
However, AGI-5198 did not result in obvious difference in TMZ-induced cytotoxicity in our 
assay (Figure S1). Taken together, our findings demonstrate that the capacity for oxidative 
metabolism is greatly limited in the presence of IDH1 mutation, suggesting a significant 
shift in energy metabolism in IDH1 mutant cells.
We then investigated the relationship between 2-HG production and cellular sensitivity to 
TMZ. To investigate whether 2-HG directly leads to chemo-sensitization for TMZ treatment, 
we analyzed cell viability in the presence of cell permeable dimethyl-2-HG by MTS assay 
(Figure 3E). We found that the 2-HG levels correlated with their vulnerability to 
chemotherapy, as the introduction of 2-HG potentiated the cytotoxic effect of TMZ. With 
500 µM TMZ treatment, 2-HG reduced cell viability by 31.0% in U87 cells. Conversely, 
increasing oxidative metabolism by introducing α-KG reversed the cytotoxic effect of TMZ 
(Figure 3F). Ten millimolar α-KG resulted in a 99.1% increase in cell viability after TMZ 
treatment. To further test the role of IDH1 mutation in chemo-sensitivity, we investigated the 
cell viability of HT-1080, a colon cancer cell line with an intrinsic IDH1R132H variant, with 
TMZ treatment (Figure 3G to H). As expected, TMZ treatment resulted in decreased cell 
viability in a dose-dependent manner. The cytotoxic effect of TMZ was alleviated by 
reducing 2-HG production via shRNA targeting of IDH1. In sum, our findings suggested an 
important role of 2-HG centered metabolic reprogramming in chemo-sensitization in IDH1 
mutant cells.
Dysfunction of PARP1 DNA repair pathway in IDH1 mutant cells
In addition to alterations in cellular metabolism, the remarkably increased susceptibility for 
acquiring DNA damage in mutant cells suggested that the chemo-sensitivity may also be 
mitigated by defunct DNA repair mechanisms, such as base excision repair (BER), 
nucleotide excision repair, mismatch repair and/or DNA recombination. A seminal study 
indicated that the metabolic defects in NAD+ productivity, prompted the vulnerability of 
IDH1 mutant cells(22). NAD+ acts as a coenzyme in many redox reactions by donating 
ADP-ribose moieties to ADP-ribosylation reactions. Importantly, NAD+ is an essential 
donor molecule for PARP-mediated single strand DNA repair. Insufficient NAD+ may 
disable PARP-associated DNA repair, which could be fatal for IDH1-mutated cells when 
confronting DNA damage. To test this hypothesis, we treated IDH1 mutant cells with TMZ, 
and olaparib (Ola), a PARP inhibitor(23). DNA damage was assessed by γH2A.X staining 
(Figure 4A). We found that TMZ-induced DNA damage was significantly enhanced when 
PARP-associated DNA repair pathway was inhibited. Quantitative analysis confirmed the 
remarkable enhancement in DNA damage (Figure 4B). Consistent with this, the comet assay 
demonstrated a significantly elongated tail formation in both IDH1WT and IDH1R132H cells 
demonstrating that the fragmented DNA is more abundant in mutant cells in either TMZ 
treatment or combination treatment involving TMZ and Ola (Figure 4C and D).
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To better understand whether PARP-associated DNA repair is a key factor that defines the 
difference in chemo-sensitivity in IDH1 mutant cells, we measured the quantity of ADP-
ribose-conjugated PARP (pADPR) through immunoblotting (Figure 4E). The formation of 
pADPR is a post-translational modification on PARP, which serves as a key step for PARP-
associated DNA repair(24). We found that TMZ treatment induced a 1.73-fold increase in 
pADPR in IDH1WT cells, suggesting a mobilization of the intrinsic DNA repair mechanisms 
during chemotherapy. Interestingly, the quantity of pADPR was found to be extensively 
reduced in untreated IDH1R132C and IDH1R132H cells (2.92 AU, 0.42 AU and 0.61 AU for 
IDH1WT, IDH1R132C and IDH1R132H, respectively). Moreover, TMZ treatment did not 
induce an obvious elevation in pADPR in mutant cells (5.05 AU, 0.01 AU and 0.82 AU for 
IDH1WT, IDH1R132C and IDH1R132H, respectively). As expected, Ola treatment depleted 
pADPR formation and completely abolished PARP-associated DNA repair, while the 
expression of PARP1 was found unchanged across all treatment groups. The significant 
difference in the pADPR/PARP ratio suggested that although PARP DNA repair machinery 
was intact, DNA damage was more likely to accumulate due to lack of NAD+ as substrate 
for BER repair. Finally, we confirmed this hypothesis by measuring changes in NAD+ in 
mutant cells (Figure 4F and S2). The total and nuclear NAD+ quantity was slightly lower in 
IDH1R132C and IDH1R132H cells without treatment. TMZ treatment reduced the quantity of 
NAD+, presumably a direct effect on pADPR formation and DNA repair. Interestingly, the 
NAD+ quantity was increased after washing out TMZ in the microenvironment, suggesting 
that active NAD+ synthesis provides substrate for BER DNA repair. The quantity of NAD+ 
was significantly reduced in mutant cells after washing off TMZ, suggesting that the NAD+ 
deficiency is the key factor causing a malfunction of BER repair (−32.6% and −25.7% in 
IDH1R132C and IDH1R132H, respectively).
Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy
The significantly enhanced DNA damage in IDH1 mutant cells that occurs as a consequence 
of inhibiting the PARP-associated DNA repair pathway suggested that a combination 
therapy could be more effective than current chemotherapy options, potentially generating a 
better tumor-inhibiting effect but at a lower dosage of chemotherapy. To better understand 
the potentiation effect of Ola in IDH1 glioma, we performed cell viability assays with 
combination therapy involving TMZ and Ola. We found that Ola potently enhanced the 
cytotoxic effect of TMZ regardless of the IDH1 mutation status (Figure 5A), as the dose-
response curves were shifted leftwards in all genotypes. For clarity, we also showed that 
while cell viability was impacted a TMZ dose of 1 mM, the addition of Ola resulted in 
remarkable potentiation of cell death at the same dose of TMZ (Figure S3). Consistent with 
the findings above, the IC50 of TMZ was significantly smaller for IDH1R132C and 
IDH1R132H cells (Table S1). Moreover, the potentiation of TMZ cytotoxicity was confirmed 
by Annexin V/PI apoptosis analysis (Figure 5B). Similar to previous findings, quantitative 
analysis showed that TMZ induced more apoptosis in IDH1 mutant cells. The population of 
apoptotic cells was significantly increased in both cell lines with the presence of Ola; 
however, IDH1 mutation predicted a more extensive cellular apoptosis (Figure 5C).
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Discussion
In the present study, we confirmed that pathogenic IDH1 mutations result in metabolic 
reprogramming and compromised oxidative metabolism. Production of 2-HG by the mutant 
enzyme activity confers a vulnerability to TMZ treatment. Furthermore, the compromised 
oxidative metabolism and decreased NAD+ pool in IDH1-mutated cells impairs the PARP-
dependent DNA repair mechanism, resulting in substantially elevated DNA damage and cell 
death. As a consequence of these molecular changes, IDH1-mutated cells are sensitized to 
therapies such as TMZ and Ola (Figure 6). TMZ treatment in tandem with DNA repair 
inhibitor is a promising therapeutic strategy for future gliomas therapies.
IDH mutation and chemo-sensitivity
Emerging studies have demonstrated the increase in chemo-sensitivity in IDH mutant 
glioma(7). Although the prognostic value of an IDH mutation in glioma has been widely 
accepted, little is known about the unique molecular features that defines the chemo-
sensitivity in IDH1 mutant cells. In the present study, we established cell line models by 
introducing IDH1 mutation in a glioma biologic background. Our cell lines recapitulate the 
molecular signatures of IDH1 mutant gliomas, such as expression of mutant enzyme, 2-HG 
production, as well as an increase in histone 3 methylation (Figure S4). Moreover, we 
confirmed that IDH1 mutant cells are more vulnerable to TMZ treatment, which replicated 
the clinically observed increased chemo-sensitivity in IDH1 mutant cells (Figure 1A). 
Additionally, analysis of apoptosis confirmed increased sensitivity to TMZ in IDH1 mutant 
cells (Figure 1B to D). These findings suggested that the IDH mutant cell line models can be 
valuable and reliable tools to understand the molecular and cellular responses to TMZ 
chemotherapy. We believe that our models are more suitable than several recently developed 
cell lines from individual patient with intrinsic IDH1 mutation. Because we introduced 
IDH1 mutants to cell lines with the same genetic background, as such the bias from 
genomic/transcriptomic variation is extensively reduced.
To validate the observed increase in chemo-sensitivity, we carefully measured DNA damage 
in IDH1 mutant cells by measuring γH2A.X as well as DNA fragmentation (Figure 2). TMZ 
treatment introduced significant DNA damage in our cell line models. Consistent with the 
changes in cell viability and fraction of apoptotic cells, we demonstrated greater DNA 
damage in IDH1- mutated cells compared with their wild type counterpart. Interestingly, we 
found an accumulation of DNA damage in untreated IDH1-mutated cells, suggesting 
elevated basal level of DNA damage resulted from the metabolic deficiencies. Presumably, 
the intrinsic DNA repair mechanism limits the baseline DNA damage to a certain extent, 
allowing the cells to survive and proliferate. In this case, mutant cells are more likely to 
suffer additional DNA damage with chemotherapy, when DNA repair mechanisms are 
compromised.
Metabolic defects in IDH-mutated cells confer cytotoxicity
Three distinct IDH enzymes, IDH1, IDH2 and IDH3, have been found in mammalian 
cells(25,26). All three enzymes catalyze the oxidative decarboxylation of isocitrate to α-KG. 
In contrast to IDH3, which is a heterotrimeric enzyme that uses NAD+ as a cofactor for it 
Lu et al. Page 8
Cancer Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
enzymatic reaction, IDH1 and 2 are homodimeric enzyme complexes and use NADP+ as 
cofactor to produce α-KG(26). Currently, only IDH1 and IDH2 mutations have been found 
in glioma cells. Neomorphic changes in IDH redirect carbon-based metabolites into 
unusable 2-HG(3,20,27). Metabolite deprivation leads to reprogramming of the Kreb’s cycle 
by altering glutamine utilization and pyruvate metabolism(27,28). The adjustment in cellular 
metabolism may limit physiologically important metabolic routes, such as ATP generation 
and macromolecule synthetic pathways, and therefore result in the increased vulnerability of 
IDH1 mutant cells. In the present study, we confirmed impaired oxidative metabolism 
(Figure 3A to C) as well as robust production of 2-HG (Figure 3D) in mutant cells. 
Moreover, introducing 2-HG to native U87 cells mimics the introduction of IDH1 mutant 
enzyme, as shown by increased cell death and chemo-sensitivity (Figure 3E). Furthermore, 
in HT-1080 cells, the TMZ chemo-sensitivity could be salvaged by enhancing cellular 
metabolism (Figure 3F) or reducing IDH1 biologic activity (Figure 3G to I). Taken together, 
our findings demonstrate reduced oxidative metabolism and 2-HG production lead to 
chemotherapy sensitization. Our finding also indicated that relieving the metabolic stress in 
IDH1-mutated cancer may prompt chemo-resistance by enhancement in cellular 
metabolism. Indeed, Molenaar et al has reported that targeting IDH1 mutation confer 
radioprotection(29). The contradictory therapeutic mechanisms between genotoxic agent and 
metabolic modulator should be considered in the future drug design and therapeutic 
strategies.
The importance of NAD+ in chemo-sensitivity in IDH1-mutated glioma
Mammalian cells develop DNA repair machinery that could be of great importance in 
maintaining genomic integrity. In cancer therapies, DNA repair pathways sometimes are 
taken advantaged to fix DNA damage sites introduced by chemotherapy. IDH1-mutated 
gliomas exhibit unique pattern in DNA repair enzymes. For example, ATRX/RAD54 is 
frequently mutated in IDH1-mutated glioma (30), whereas other DNA repair enzymes, such 
as ATM, CHEK1, CHEK2, and RAD52, are amplified in the genome of IDH1-mutated 
glioma (Figure S5). Several studies shed light on the changes in DNA repair mechanism in 
IDH1-mutated cells, including RAD51 and ATM pathways (14,15). In-depth study is 
encouraged to elucidate the unique pattern in DNA repair mechanisms in IDH1-mutated 
glioma, and therefore better guide drug discovery and cancer therapy. The question whether 
DNA repair mechanism is the key factor that determines in the chemo-sensitivity in IDH1-
mutated cells remains unanswered. A seminal study by Tateishi et al. highlighted the 
essential role of NAD+ in IDH1-mutated glioma, suggesting that impairment of NAD+ 
synthesis could be one of the key metabolic defects in IDH mutant cells(22). In metabolic 
intact cells, the NAD concentrations in each of the subcellular compartment are steadily 
maintained (31). IDH1 mutant deplete NAD in all subcellular compartment due to inhibition 
of Naprt1 activity. Targeting the damaged NAD synthetic pathway by Nampt inhibitors 
FK866 or GMX1778 further limit the availability of NAD (22). In additional to the many 
important roles in cellular metabolism and redox balance, NAD+ plays a key role in BER 
pathway through PARP(24). Indeed, our results confirmed that PARP1 is essential for DNA 
repair during TMZ treatment, as chemical inhibition of PARP1 through Ola significantly 
potentiated TMZ induced DNA damage (Figure 4A-C). Interestingly, we observed a 
significant reduction in NAD+ in IDH1 mutant cells (Figure 4F), which confirmed that the 
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limited DNA repair capacity in IDH1 mutant cells is caused by insufficient substrate for the 
biological function of PARP. Additionally, we observed pADPR, the intermediate molecule 
that represents active PARP DNA repair, is depleted in IDH1 mutant cells (Figure 4D). TMZ 
treatment led to an induction of pADPR formation in cells with wild type IDH1, but not the 
mutant cells, suggesting a significantly reduced DNA repair mechanism in IDH1 mutant 
cells. Interestingly, the amount of total PARP remained stable within all the treatments, 
suggesting the vulnerability based on functional ablation of DNA repair, but not changes in 
the level of expression. Notably, several recent findings showed PARP inhibition further 
damages energy metabolism, which may exert synergistic effect with genotoxic agents 
(32,33). In summary, our findings extend the current understanding of the molecular 
mechanisms that determine the vulnerability to NAD+ depletion in IDH1-mutated gliomas, 
through compromised PARP-associated DNA repair.
Combined treatment of TMZ and Ola is a promising therapeutic strategy for IDH-mutated 
gliomas
Radiation with daily TMZ followed by adjuvant TMZ is the current standard care for newly 
diagnosed glioblastoma. Compared to radiation therapy alone, additional TMZ 
chemotherapy extends median survival from 12.1 to 14.6 months(34,35). Despite the clear 
statistical improvement of this regimen compared to radiation alone, less than one third of 
the patients survive beyond 2 years. A phase III study in patients with grade II glioma 
provided the level I evidence that radiation therapy plus chemotherapy should be considered 
a new standard of care for patients who had subtotal resection and older than 40 years old 
(Mehta et al, 2014 RTOG9802). Although patients with low grade glioma survive longer 
following radiation plus chemotherapy compared with those who receive radiation only, the 
current standard care hasn’t prevented the lower grade tumor from going through higher 
grade transformation. Despite the fact that patients with IDH-mutated glioma have a better 
prognosis compared to those whose tumors lack this mutation a fatal clinical outcome is 
seen in nearly all patients with IDH-mutated lower grade glioma. Therefore, developing 
more effective therapies remain an important priority for patients with even lower grade 
gliomas.
As an orally available alkylating agent, TMZ has been widely used in lower grade glioma. 
Our study has provided the preclinical evidence that combined treatment with TMZ and 
Olaparib is more effective in against IDH-mutated glioma compared to the IDH wild type 
tumors. IDH-mutated tumor exhibited deficiency in NAD+ production and pAPDR 
production, whereas greatly limited the PARP DNA repair pathway (Figure 4E and F). The 
addition of Olaparib, an inhibitor of PARP, targeting a “selective vulnerability” of IDH-
mutated tumors, further limiting DNA repair, leading to more DNA damage and cell death 
(Figure 5).
The synergistic effects between TMZ and Olaparib in patients with the IDH mutation 
provides the possibility to achieve better cytotoxic effect with less amount of alkylating 
agent, which leads to the reduced toxicities and improved patients’ quality of life(36,37). 
The findings from our study provide the foundation for a hypothesis driven clinical 
therapeutic study the clinical efficacy of the combined treatment of TMZ and Olaparib in 
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IDH-mutated glioma; prospectively investigating IDH mutation status as a predictive marker 
for this combined therapy.
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Figure 1. IDH1 mutant glioma cells are sensitive to TMZ
A. TMZ dose-response curves of U87 MG and U251 MG cells with IDH1 mutation for 96 
hr (n=3).
B. Annexin-V apoptosis analysis of IDH1 mutant cell with TMZ treatment.
C. Cell cycle analysis of IDH1 mutant cells with TMZ treatment (left panel). The overview 
of cell cycle progression with clear G2/M arrest (right panel).
D. DNA fragmentation test for IDH1 mutant cells treated with TMZ.
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Figure 2. Enhanced DNA damage in IDH1 mutant glioma cells
A. Western blotting for γH2A.X expression in IDH1 mutant cells. Protein expression level 
was determined by densitometry analysis.
B. Immunostaining for γH2A.X puncta in IDH1 mutant cells.
C. Comet assay demonstrates DNA fragmentation in IDH1 mutant cells.
D. Quantitative analysis showed enhancement in DNA fragmentation in IDH1-mutated cells.
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Figure 3. Metabolic reprogramming results in chemo-sensitivity in IDH1 mutant cells
A. Seahorse XF Cell Mito Stress analysis showed alteration in oxidative metabolism in 
IDH1 mutant cells (n=4).
B. Quantification of baseline oxidative metabolism in IDH1 mutant cells (n=4, **p<0.01).
C. Quantification of maximum oxidative metabolism in IDH1 mutant cells (n=4, **p<0.01).
D. Quantification of D-2-HG in IDH1 mutant cells. AGI-5198 treatment (1 µM) was used to 
determine specific activity from IDH1 mutant enzyme (n=3, **p<0.01)
E. Cell viability assessment of U87 MG cells in the presence of TMZ and dimethyl-2-HG 
(n=3).
F. Cell viability measurement of HT-1080 cells with the presence of TMZ and dimethyl-α-
KG (n=3, *p<0.05 as compared with DMSO group, #p<0.05 as compared to TMZ group).
G. Cell viability assessment of HT-1080 cells with stable expression of IDH1 shRNA (n=3, 
*p<0.05 as compared to 0 µM TMZ, #p<0.05, ##p<0.01 as compared to scramble RNA)
H. Quantitative PCR (upper panel) and western blot analysis (lower panel) for IDH1 
expression in HT-1080 cells (n=3).
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Figure 4. Dysfunction of the PARP1 DNA repair pathway in IDH1 mutant cells
A. Immunostaining of γH2A.X in IDH1 mutant cells treated with TMZ and Ola (Bar=10 
µm).
B. Quantification of γH2A.X puncta in IDH1 mutant cells treated with TMZ and Ola (n=3, 
*p<0.05, **p<0.01).
C. Comet assay measuring DNA fragmentation in IDH1 mutant cells treated with TMZ and 
Ola.
D. Quantification of DNA fragmentation in IDH1 mutant cells.
E. Western blot analysis of pADPR, PARP and β-actin expression in IDH1 mutant cells 
treated with TMZ and Ola.
F. Quantification of NAD in IDH1 mutant cells treated with TMZ (n=3, *p<0.05, **p<0.01).
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Figure 5. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by 
chemotherapy
A. Dose-response curves for IDH1 mutant cells treated with TMZ and Ola (n=3).
B. Annexin-V apoptosis analysis demonstrated the potentiation effect of Ola for TMZ 
chemotherapy.
C. Quantification of apoptotic cells in IDH1 mutant cells treated with TMZ and/or Ola.
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Figure 6. Impaired PARP1 DNA repair defines chemo-sensitivity
Chemotherapy induces damages in chromosomal DNA in cancer cells. PARP serves an 
important role in maintaining genomic integrity and counteract with chemo-agent. In tumors 
with IDH mutation, cells are less capable of maintaining DNA repair mechanism, as 
deficiency in NAD+ metabolism deprives substrates for the BER pathway. Targeting PARP 
by olaparib significantly potentiates the therapeutic effect of TMZ in IDH mutant cells.
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